Back to Biomarkers List
Associated Genetic Biomarkers
Bromodomain containing 4 (BRD4) is a gene that encodes a protein that associates with human RING3 protein and chromosomes during mitosis. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
BRD4 is altered in 2.38% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and cutaneous melanoma having the greatest prevalence of alterations .
The most common alterations in BRD4 are BRD4 Mutation (1.85%), BRD4 Amplification (0.30%), BRD4 Fusion (0.08%), BRD4-NOTCH3 Fusion (0.04%), and BRD4 Loss (0.03%) .
BRD4 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain BRD4 status as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
Trials with BRD4 status in the inclusion eligibility criteria most commonly target bladder carcinoma, lymphoma, malignant solid tumor, and urothelial carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are BRD4 Fusion and BRD4 Mutation .
Bms-986158 and olaparib are the most frequent therapies in trials with BRD4 as an inclusion criteria .
Significance of BRD4 in Diseases
Urothelial Carcinoma +
Malignant Solid Tumor +
Bladder Carcinoma +
Central Nervous System Lymphoma +
BRD4 is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRD4 status and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) .
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.